Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 14
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Sanofi SA
SNY
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$39.84
0.72
1.84%
Ult. Agg.: Oct 14, 11:36 AM
$39.37
0.25
0.64%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Dividendi
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Sanofi Financials
Sanofi (SNY) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D
Sanofi (SNY) Q2 sales hit $13.48B, beating estimates driven by Dupixent's 37.6% surge. Full details on earnings and 2026 outlook.
Vandana Singh
PRO
Sanofi Sees FY2026 Sales $55.789B vs $55.850B Est
Sanofi (NASDAQ:SNY) sees FY2026 sales of $55.789 billion vs $55.850 billion analyst estimate.
Benzinga Newsdesk
PRO
Sanofi Q2 Adj. EPS $1.21 Beats $1.09 Estimate, Sales $13.482B Beat $12.650B Estimate
Sanofi (NASDAQ:SNY) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.09 by 11.01 percent. This is a 34.44 percent increase over earnings of $0.90 per share from the same
Benzinga Newsdesk
Why Novavax Stock Is Trading Higher On Wednesday?
Novavax shares rise after Q1 revenue beat; partnerships, credit facility, and technical levels shape outlook amid shift to net loss.
Vandana Singh
Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe
Regeneron beats Q1 estimates as Eylea HD demand rises, while margins narrow and FDA decisions on manufacturing remain pending.
Vandana Singh
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat
Sanofi, Regeneron win FDA nod for Dupixent in pediatric CSU as Q1 sales beat estimates, driven by strong Dupixent growth.
Vandana Singh
